Affinity Asset Advisors »

Arrivent Biopharma shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $3.0M 150k 20.12

More positions owned by Affinity Asset Advisors

Spdr Series Trust State Street Spd Put Option (XBI)
Apogee Therapeutics (APGE)
Insmed Com Par $.01 (INSM)
Abivax Sa Sponsored Ads (ABVX)
Ishares Tr Ishares Biotech Call Option (IBB)
Ventyx Biosciences (VTYX)
Xenon Pharmaceuticals (XENE)
Praxis Precision Medicines I Com New (PRAX)
Cytokinetics Com New (CYTK)
Amgen (AMGN)
Spyre Therapeutics Com New (SYRE)
Wave Life Sciences SHS (WVE)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Select Sector Spdr Tr State Street Hea Call Option (XLV)
Roivant Sciences SHS (ROIV)

View all positions for Affinity Asset Advisors

Top funds holding Arrivent Biopharma

Suvretta Capital Management
Hillhouse Capital Advisors
Infinitum Asset Management
FMR
OrbiMed Advisors
BlackRock
Octagon Capital Advisors
Novo A/S
Vanguard Group
Sofinnova Ventures
General Catalyst Group Management
State Street Corporation
Geode Capital Management
Goldman Sachs Group
Siren

View all funds holding Arrivent Biopharma